Annotated CRF

CI	M Pharmaceuticals, Inc.			
	Subject ID 044 -	- 1 🗌		
	Subject Initials			
	INCLUS	Eligib	ility	
Inc	clusion Criteria (all answers must be YES to be included in the trial)	Yes	No	
1	Age 18-45 years, inclusive	🔲 1	□ 0	inc1
2	Willingness to submit to diagnostic machine testing	🔲 1	□ o	inc2
3	Male or non-pregnant, non-lactating female. Women of reproductive potential must be practicing adequate contraception (e.g., intrauterine device or double barrier device such as a diaphragm or condom plus spermicide). Abstinence is not considered to be an acceptable method of contraception. Additionally, women of reproductive potential must have a negative urine pregnancy at screening and prior to enrollment.	:	o	inc3
4	In good health as determined by medical history and physical examinations	🔲 1	□ 0	inc4
5	Capable of understanding and complying with the protocol and has signed the informed		_	
_	consent documentEXCLUS	ш.	∐ 0	inc5
	clusion Criteria (all answers must be NO to be included in the trial)	Yes	No	
1	Pregnant or lactating females			exc1
2	History of anaphylaxisHistory or presence of hepatitis			exc2 exc3

CM Pharmaceuticals, Inc.		Subject ID 044 - 1
		Subject Initials
		subjinit \$3 Demographics/Medical History
		<u> </u>
DEMO		
Demographics Sex: sex \$1 Race: □ 1 Male □ 1 Cauca □ 2 Female □ 5 Other	race \$9 asian asiar (specify):	₂ Black
Date of Birth: birthdt / birthdt / dd / y	<u></u>	Date Informed Consent Signed :/_icdt /
LABSDONE		
Pregnancy test Ibdsam Result:		ive Ibdrescd 2 Not applicable
	□ ₀ Negati	ve ibulescu 2 Not applicable
MEDHIST Medical History		
Body System	Normal	Abnormal (describe)
Neuro mhbodsys \$26	mhstatcd 0	mhterm \$200
HEENT	□ o	
Heart	□ o	
Lungs	□ o	
Abdomen	□ o	
Musculoskeletal	□ o	
Peripheral Vascular	□ o	
Skin	□ o	
Additional Findings:		mhafsp \$200

M Pharmaceutica	ls, Inc.		Sı	ubject ID 044 - 1
				Subject Initials
				Physical Examinat
PE				
		Study Day 1 peptm \$11		Study Day 2
Body System	Normal	Abnormal (describe)	Normal	Abnormal (describe)
Neurological pebodsys \$21	pestatcd 0	pefind \$160	□ o	pechgcd ☐ ₁ Unchanged from Study Day 1
HEENT	□ o		o	☐ ₁ Unchanged from Study Day 1
Heart	□ o		□ o	☐ ₁ Unchanged from Study Day 1
Lungs	□ o		О	☐ 1 Unchanged from Study Day 1
Abdomen	o		О	☐ 1 Unchanged from Study Day 1
Musculoskeletal	o		О	☐ 1 Unchanged from Study Day 1
Peripheral Vascular	o		□ o	☐ 1 Unchanged from Study Day 1
Skin	o		o	☐ 1 Unchanged from Study Day 1
Additional Findings:			□₄Uncha	nged from Study Day 1

CM Pharmaceuticals, Inc.	Subject ID 044 - 1
	Subject Initials
	Laboratory

	-	
LABS	lbptm \$11 Study Day 1	Study Day 2
Name of Lab	Ibnamecd Ibname \$50	
lbtest \$16 Lab test	Result	Result
	Ibstresn	
	☐ ₁ Not Done	☐ ₁ Not Done
Sodium		
Potassium		
Chloride		
BUN		
Creatinine		
Total Protein		
Albumin		
Direct bilirubin		
Total bilirubin		
ALT/SGPT		
AST/SGOT		
LDH		
WBC		
Neutrophils		
Eosinophils		
Basophils		
Lymphocytes		
Monocytes		
Hct%		
Hgb		
Platelets		
INR		
PT		
PTT		

44 - 1 🔲 🔲
ials
s and Dosing
O ₂ Sat (%)
o2sat
ire Score
Post
od #2
g/kg
l/kg
infused
_ mg

CM Pharmaceuticals, Inc.		Subject ID 044 - 1
		Subject Initials
VITALTPT	Study Day 1	Vital Signs
VITALTPT \$31		

Timepoint	Time (24 Hour)	HR (per min)	BP (syst/dia)	O ₂ Sat (%)
- 5 minutes	vsacttm :	heart	sysbp / diapb	o2sat
0 minutes	:		1	
5 minutes	:		1	
10 minutes	:		1	
15 minutes	:		1	
20 minutes	:		1	
25 minutes	:		1	
30 minutes	:		1	
35 minutes	:		1	
40 minutes	:		1	
45 minutes	:		1	
50 minutes	:		1	
55 minutes	:		1	
60 minutes	:		1	
65 minutes	:		1	
70 minutes	:		1	
End of Infusion Period #2	:			
1 hour after Infusion Period #2	:		1	

CM P	harmaceuticals, Inc.				Subject ID	044 - 1 🔲 🗀
					Subject	t Initials 🔲 🔲 🦳
		CONME	DS		Concomit	ant Medications
□ ₀ N	Ione cmanycd					
	Medication	Dose	Unit	Route	Date (mm / dd / yy)	Time (24 Hour)
1	cmterm \$80	cmdose \$10	cmunit \$10	cmroute \$10	cmstdtc \$10	cmtm :
2	Coding: cmprefcd \$11 - V	VHO Drug		erm		:
3	cmatccd \$5 - AT cmatc \$50 - ATC					:
4						:
5						·
6						·
7						·
8						·
9						·
10					/	:
11						:
12						:
		_			☐ Check if	subsequent pages

СМ Г	Pharmaceuticals, Inc.							
		F	-	ıs Adverse Even DIATELY	its	Subject	ID 044 - 1]
						Subje	ect Initials 🔲 🔲	
		AE					Adverse Event	:s
□ o	None aeanycd							
	Event Description		Onset	Resolution	Severity	Relationship to PROD	Actions taken (✓ all applicable)	
1	aeterm \$120	Date (mm/dd/yy) Time (24 hour)	aestdt aesttm	aeendt aeentm : Continuing	☐ 1 Mild ☐ 2 Moderate ☐ 3 Severe ☐ 4 Life-threatening aesevcd	1 Unrelated 2 Possibly 3 Probably 4 Definitely aerelcd	☐ None aenoatcd ☐ Treatment aetxcd ☐ PROD stopped ← ☐ Discontinued trial← ☐ SAE Reported←	aeprencd aedccd aeserc
2		Date (mm/dd/yy) Time (24 hour)	/:	aeongocd : : : : : : : : : : : : : : : : : : :	☐ 1 Mild ☐ 2 Moderate ☐ 3 Severe ☐ 4 Life-threatening	☐ 1 Unrelated ☐ 2 Possibly ☐ 3 Probably ☐ 4 Definitely	☐ None ☐ Treatment ☐ PROD stopped ☐ Discontinued trial ☐ SAE Reported	
3		Date (mm/dd/yy) Time (24 hour)	/:	/	☐ 1 Mild ☐ 2 Moderate ☐ 3 Severe ☐ 4 Life-threatening	☐ 1 Unrelated ☐ 2 Possibly ☐ 3 Probably ☐ 4 Definitely	☐ None ☐ Treatment ☐ PROD stopped ☐ Discontinued trial ☐ SAE Reported	
4		Date (mm/dd/yy) Time (24 hour)	/:		☐ 1 Mild ☐ 2 Moderate ☐ 3 Severe ☐ 4 Life-threatening	☐ 1 Unrelated ☐ 2 Possibly ☐ 3 Probably ☐ 4 Definitely	☐ None ☐ Treatment ☐ PROD stopped ☐ Discontinued trial ☐ SAE Reported	
		Cod	ding: aeprefcd \$8 -				· •	
) - Medra Preferred T	erm			
lnv	estigator's Signature		aesoccd \$8 - 9 aesoc \$100 -			Date ☐₁ Check if su	bsequent pages	

C4d.	v Commistic		dy Da		VITAL.vsdt// _mm ddy	Stu	dy Comp
	Signs	n/Terminatior	ı VII <i>F</i>	<u> </u>			
	Time (24 Hour)	Temp	(1	HR per minute)	RR (per minute	BP) (syst/dia	O ₂ (%
	:	(1)	- (oci illinato,	(por minute	/ (Systial)	, (,
If No,	please comp	nplete the trial	ing (√ a			dsstatcd T	
Rea	ason for disco			Date / dd / yy			
1	Adverse Ever	nt lecd	/ _d	saedt	event:	dsaesp \$14	10
Usabeta dsaded withdrew consent dswdcd		/	1	reason:	dswdsp \$40	0	
З	Lost to follow	up	/	swddt /	reason:	dslostsp \$14	10
<u></u>	Blood clot	estcd	ds	slostdt /			
	Other	otcd	ds	shntdt	specify:	dsothsp \$20	20
5		thcd	/ <u>ds</u>	othdt	specify.	usotrisp \$20	JU
Was t	he protocol for please comp	ocol Complia ollowed withou lete the follow irtures	ut devia		OLINANAA.	oNo departcd	
□ 1	Entrance Crite			specify:	r	eassp1 \$200	
			b.c				
		dministered ful	ıy	reason:	r	eassp2 \$200	
3	Images not of		ot	explain:			
□ 4		ot obtained or n cheduled time p		explain:			
	Other			specify:			
<u></u> 5							